IDENTIFICATION OF POTENTIAL DRUGS FOR PREVENTING CORONARY ARTERY DISEASE IN POST-COVID PATIENTS THROUGH MOLECULAR DYSREGULATION ANALYSIS: A TRANSCRIPTOMIC STUDY

Clicks: 14
ID: 331350
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #280 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Coronavirus disease 2019 (COVID-19) is associated with an increased long-term risk of cardiovascular complications, including coronary artery disease (CAD), but the molecular mechanisms underlying this association remain unclear. This study aimed to identify transcriptomic signatures linking post-COVID status to CAD and to explore candidate drugs for preventive intervention. Methods Peripheral blood mononuclear cell transcriptomic datasets from convalescent COVID-19 (GSE202805) and CAD (GSE12288) were obtained from the Gene Expression Omnibus database. Differentially expressed genes were identified using DESeq2 with thresholds of adjusted P < 0.05 and |log2 fold change| ≥ 1. Enrichment analyses were performed using clusterProfiler, followed by protein-protein interaction network analysis and signature-reversal drug repurposing. Results Post-COVID samples showed 1,423 upregulated and 465 downregulated genes, whereas CAD samples showed 434 upregulated and 370 downregulated genes. Cross-comparison identified two sets of oppositely regulated genes, including 13 genes upregulated in post-COVID but downregulated in CAD, and 8 genes with the reverse pattern. Functional enrichment in post-COVID highlighted persistent immune activation, cytokine signalling, and endothelial dysregulation, whereas CAD was enriched for vascular remodelling, extracellular matrix interaction, and PI3K-Akt signalling. Protein interaction analysis identified RAD51, ESR1, and GADD45B as key candidate genes. Drug repurposing analysis prioritized histone deacetylase inhibitors and anti-inflammatory pathway inhibitors, including vorinostat, apicidin, and fedratinib. Conclusion Persistent inflammatory and vascular disturbances after COVID-19 may contribute to increased CAD risk. RAD51, ESR1, and GADD45B may represent promising molecular targets for prevention, with several repurposed drugs emerging as potential candidates for further validationFigure 1.Workflow of transcriptomic and network pharmacology analyses for identifying potential drug candidates linking post-COVID status and coronary artery disease
Reference Key
openalex_W7220446379 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A F Hendrawan, M A Prazeva, H Widyaningtyas, M H S Lesmana
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.007
URL
https://doi.org/10.1093/eurheartjsupp/suag119.007
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.